Drug Trial Radar · NCT03267940
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
85
Actual
Start
Oct 2, 2017
Primary completion
Nov 11, 2019
Study completion Nov 11, 2019
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).
Conditions
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma, Intrahepatic
- Cholangiocarcinoma, Extrahepatic
- Gallbladder Adenocarcinoma
Interventions
PEGPH20Drug
PEGPH20 will be administered as per the schedule specified in the respective arms.
CISDrug
CIS will be administered as per the schedule specified in the respective arms.
GEMDrug
GEM will be administered as per the schedule specified in the respective arms.
AtezolizumabDrug
Atezolizumab will be administered as per the schedule specified in the respective arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Run-in Portion: Number of Participants With Adverse Events (AEs)Time frame: From first exposure to study drug through 30 days after the end of treatment visit (maximum exposure: 508 days)
- Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Hematology and Blood Chemistry)Time frame: From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days)
- Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) and Vital SignsTime frame: From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days)
- Run-in Portion: Number of Participants With AEs Leading to Dose Reduction or Interruption of Any Study MedicationTime frame: From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days)
- Expansion Portion: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1: Percentage of Participants With Objective ResponseTime frame: From date of randomization until the date of first documented progression of disease or date of death from any cause, whichever came first (maximum exposure: 421 days)
Locations
36 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic of Arizona
Phoenix, Arizona
University of Arizona
Tucson, Arizona
City of Hope
Duarte, California
Scripps
La Jolla, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
University of California Irvine Division of Hematology-Oncology, Department of Medicine UC Irvine Health
Orange, California
UC Davis
Sacramento, California
UCLA - David Geffen School of Medicine
Santa Monica, California
The Oncology Institute of Hope and Innovation
Whittier, California
Yale Cancer Center
New Haven, Connecticut
Lombardi Cancer Center, Georgetown University
Washington D.C., District of Columbia
Johns Hopkins
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Mount Sinai
New York, New York
University of Rochester Medical Center
Rochester, New York
Duke Cancer Institute
Durham, North Carolina
Gabrail Cancer Center
Canton, Ohio
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
MD Anderson Cancer Center
Houston, Texas
UT Health Cancer Center
San Antonio, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Mason
Seattle, Washington
Seattle Cancer Care Alliance
Seattle, Washington
Froedtert Hospital And Medical College
Milwaukee, Wisconsin
Samsung Medical Center
Seoul, Gangnam-gu, South Korea
Korea University Guro Hospital
Seoul, Guro-gu, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
The Catholic University of Korea Seoul St. Mary's Hospital
Seoul, Seocho-gu, South Korea
Severance Hospital, Yonsei University Health System
Seoul, Seodaemun-Gu, South Korea
Asan Medical Center
Seoul, Songpa-gu, South Korea
Prince of Songkla University
Hat Yai, Changwat Songkhla, Thailand
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, Muang, Thailand
King Chulalongkorn Memorial Hospital
Bangkok, Patumwan, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.